Ani Pharmaceuticals Stock Performance
| ANIP Stock | USD 77.41 0.05 0.06% |
The firm shows a Beta (market volatility) of 0.4, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, ANI Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding ANI Pharmaceuticals is expected to be smaller as well. At this point, ANI Pharmaceuticals has a negative expected return of -0.0511%. Please make sure to confirm ANI Pharmaceuticals' maximum drawdown, as well as the relationship between the accumulation distribution and market facilitation index , to decide if ANI Pharmaceuticals performance from the past will be repeated in the future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days ANI Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable forward indicators, ANI Pharmaceuticals is not utilizing all of its potentials. The current stock price agitation, may contribute to short-term losses for the retail investors. ...more
Actual Historical Performance (%)
One Day Return 0.86 | Five Day Return (5.72) | Year To Date Return (1.36) | Ten Year Return 160.73 | All Time Return (63.81) |
Last Split Factor 1:6 | Last Split Date 2013-07-18 |
1 | ANI Pharmaceuticals Director Renee Tannenbaum Sells 1,800 Shares | 12/10/2025 |
2 | Is ANI a Solid Growth Stock 3 Reasons to Think Yes | 12/22/2025 |
3 | Intellia Stock Declines Around 55 percent in 3 Months Heres Why | 01/05/2026 |
4 | Disposition of 500 shares by Meredith Cook of ANI Pharmaceuticals at 84.33 subject to Rule 16b-3 | 01/13/2026 |
5 | ANI Pharmaceuticals Targets 1B 2026 Revenue as Rare Disease Pivot Accelerates, Cortrophin Leads Growth | 01/14/2026 |
6 | ANI Pharmaceuticals VP Meredith Cook Sells 500 Shares of Stock | 01/15/2026 |
7 | Is ANI Pharmaceuticals Stock Outpacing Its Medical Peers This Year | 01/16/2026 |
8 | Has The ANI Pharmaceuticals Share Price Rally Left Further Upside On The Table | 01/22/2026 |
9 | ANI Pharmaceuticals Stock Analysis Exploring A 35.71 percent Potential Upside - DirectorsTalk Interviews | 01/27/2026 |
10 | Are Medical Stocks Lagging Aldeyra Therapeutics This Year | 02/03/2026 |
11 | Is ANI Pharmaceuticals a Great Value Stock Right Now | 02/06/2026 |
12 | ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026, at 800 a.m. ET | 02/13/2026 |
| Begin Period Cash Flow | 221.1 M | |
| Total Cashflows From Investing Activities | -404.7 M |
ANI Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 8,107 in ANI Pharmaceuticals on November 18, 2025 and sell it today you would lose (366.00) from holding ANI Pharmaceuticals or give up 4.51% of portfolio value over 90 days. ANI Pharmaceuticals is currently does not generate positive expected returns and assumes 2.1988% risk (volatility on return distribution) over the 90 days horizon. In different words, 19% of stocks are less volatile than ANI, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
ANI Pharmaceuticals Target Price Odds to finish over Current Price
The tendency of ANI Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 77.41 | 90 days | 77.41 | under 95 |
Based on a normal probability distribution, the odds of ANI Pharmaceuticals to move above the current price in 90 days from now is under 95 (This ANI Pharmaceuticals probability density function shows the probability of ANI Stock to fall within a particular range of prices over 90 days) .
ANI Pharmaceuticals Price Density |
| Price |
Predictive Modules for ANI Pharmaceuticals
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as ANI Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.ANI Pharmaceuticals Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. ANI Pharmaceuticals is not an exception. The market had few large corrections towards the ANI Pharmaceuticals' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold ANI Pharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of ANI Pharmaceuticals within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.22 | |
β | Beta against Dow Jones | 0.40 | |
σ | Overall volatility | 2.67 | |
Ir | Information ratio | -0.12 |
ANI Pharmaceuticals Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of ANI Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for ANI Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| ANI Pharmaceuticals generated a negative expected return over the last 90 days | |
| The company reported the previous year's revenue of 614.38 M. Net Loss for the year was (18.52 M) with profit before overhead, payroll, taxes, and interest of 502.34 M. | |
| ANI Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Over 98.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from finance.yahoo.com: ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026, at 800 a.m. ET |
ANI Pharmaceuticals Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of ANI Stock often depends not only on the future outlook of the current and potential ANI Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. ANI Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 19.3 M | |
| Cash And Short Term Investments | 151.2 M |
ANI Pharmaceuticals Fundamentals Growth
ANI Stock prices reflect investors' perceptions of the future prospects and financial health of ANI Pharmaceuticals, and ANI Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on ANI Stock performance.
| Return On Equity | 0.0866 | ||||
| Return On Asset | 0.0237 | ||||
| Profit Margin | 0.05 % | ||||
| Operating Margin | 0.10 % | ||||
| Current Valuation | 2.09 B | ||||
| Shares Outstanding | 22.46 M | ||||
| Price To Earning | 43.35 X | ||||
| Price To Book | 3.44 X | ||||
| Price To Sales | 2.10 X | ||||
| Revenue | 614.38 M | ||||
| Gross Profit | 502.34 M | ||||
| EBITDA | 63.12 M | ||||
| Net Income | (18.52 M) | ||||
| Cash And Equivalents | 63.38 M | ||||
| Cash Per Share | 3.89 X | ||||
| Total Debt | 624.09 M | ||||
| Debt To Equity | 0.85 % | ||||
| Current Ratio | 3.35 X | ||||
| Book Value Per Share | 24.19 X | ||||
| Cash Flow From Operations | 64.02 M | ||||
| Earnings Per Share | 1.60 X | ||||
| Market Capitalization | 1.74 B | ||||
| Total Asset | 1.28 B | ||||
| Retained Earnings | (100.28 M) | ||||
| Working Capital | 334 M | ||||
| Current Asset | 192.58 M | ||||
| Current Liabilities | 11.76 M | ||||
About ANI Pharmaceuticals Performance
Assessing ANI Pharmaceuticals' fundamental ratios provides investors with valuable insights into ANI Pharmaceuticals' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the ANI Pharmaceuticals is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 179.58 | 182.58 | |
| Return On Tangible Assets | (0.02) | (0.03) | |
| Return On Assets | (0.01) | (0.01) | |
| Return On Equity | (0.04) | (0.04) |
Things to note about ANI Pharmaceuticals performance evaluation
Checking the ongoing alerts about ANI Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for ANI Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| ANI Pharmaceuticals generated a negative expected return over the last 90 days | |
| The company reported the previous year's revenue of 614.38 M. Net Loss for the year was (18.52 M) with profit before overhead, payroll, taxes, and interest of 502.34 M. | |
| ANI Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Over 98.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from finance.yahoo.com: ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026, at 800 a.m. ET |
- Analyzing ANI Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether ANI Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining ANI Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating ANI Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of ANI Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of ANI Pharmaceuticals' stock. These opinions can provide insight into ANI Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for ANI Stock Analysis
When running ANI Pharmaceuticals' price analysis, check to measure ANI Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ANI Pharmaceuticals is operating at the current time. Most of ANI Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ANI Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ANI Pharmaceuticals' price. Additionally, you may evaluate how the addition of ANI Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.